Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adamas Pharmaceuticals, Inc.
Age
30–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed a current IRB/IEC-approved informed consent form
Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
On a stable regimen of antiparkinson's medications , including any levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation
Experiencing troublesome dyskinesia following levodopa dosing (peak dose dyskinesia)
Able to understand and complete a standardized PD home diary, following training
You may not be if
History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation)
History of seizures or stroke/TIA within 2 years of screening
History of cancer within 5 years of screening, except adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer
Estimated GFR \< 50 mL/min/1.73m2
Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening
If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose
If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment
Treatment with an investigational drug or device within 30 days prior to screening
Treatment with an investigational biologic within 6 months prior to screening
